treatment with LAIs. On the other hand, only 9.7 (15/158) % of patients thought that LAIs is "very suitable" or "suitable" for them. More than half of patients thought that LAIs are fewer side effects and more reliable therapeutic option. Conclusions: Our results clarified the gaps of attitudes toward LAIs between psychiatrists and patients with schizophrenia. Positive impression concerning side effects may promote uptake of newer LAIs.
controlled trial compared adjunctive benzoate (1 g/day) plus sarcosine (2 g/day) vs. sarcosine (2 g/day) for clinical symptoms, cognitive function, and global functioning of chronic schizophrenia patients who have been stabilized with various second-generation antipsychotics. Participants were measured with the Positive and Negative Syndrome Scale and the Global Assessment of Functioning Scale every 3 weeks. Seven cognitive domains, recommended by the Measurement and Treatment Research to Improve Cognition in Schizophrenia Committee, were measured at weeks 0 and 12. Results: Combination of both NMDA-enhancing agents, rather than sarcosine alone or placebo, improved global functioning and the global composite score of all 7 cognitive domains of patients with schizophrenia while their clinical symptoms remained unimproved. Discussion: Our previous study showed that add-on benzoate improved cognitive function and clinical symptoms of chronic schizophrenia patients who had been stabilized at haloperidol or risperidone. Whether the cognitive improvement was secondary to symptom reduction remained uncertain. The findings of the current study plus the previous study suggest that NMDAenhancement therapy can improve the cognitive function of patients with schizophrenia, supporting the pro-cognitive effect can be primary no matter whether clinical symptoms improve or not.
